XORTX Therapeutics
XRTX
4 hedge funds and large institutions have $8.01K invested in XORTX Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
0.15% less ownership
Funds ownership: 0.23% → 0.08% (-0.15%)
97% less capital inflows, than outflows
Capital inflows: $522 | Capital outflows: $18.3K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$261 |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$261 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$18.3K |
XRTX Hedge Fund Activity: Q3 2023 in Review
4 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q3 2023, worth a combined $8.01K — down 70% from $26.6K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new XRTX positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $261. The largest seller was Citadel Advisors, exiting entirely with an estimated $18.3K sold.
- 4 institutional investors held XORTX Therapeutics (XRTX) as of Q3 2023, up from 3 in Q2 2023.
- Funds reported $8.01K of XORTX Therapeutics stock for Q3 2023, down 70% quarter-over-quarter.
- 2 funds opened new XORTX Therapeutics positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest XORTX Therapeutics buyer in Q3 2023 was Royal Bank of Canada, an estimated $261 added.
- The largest XORTX Therapeutics seller in Q3 2023 was Citadel Advisors, an estimated $18.3K sold.
Based on aggregated 13F filings for Q3 2023.